References
- Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006; 27: 1056–65
- Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Va-leyre D, et al. Pulmonary Lymphangioleiomyomatosis: A Study of 69 Patients. Medicine 1999; 78: 321–337
- Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangi-oleiomyomatosis. Cancer Contr 2006; 13: 276–85
- Laverdiere C, David M, Dubois J, Russo P, Hershon L, Lapierre JG. Improvement of disseminated lymphangiomatosis with recombinant interferon therapy. Pediatr Pulmonol 2000; 29: 321–4
- Klein M, Krieger O, Ruckser R, Rosen A, Waldner R, Preis P, et al. Treatment of lymphangioleiomyomatosis by ovariec-tomy, interferon alpha 2b and tamoxifen—a case report. Arch Gynecol Obstet 1992; 252: 99–102
- Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609–17
- Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and pa-tients survival. Am J Transplant 2001; 1: 179–84
- Viral hepatitis guidelines in hemodialysis and transplanta-tion. Am J Transplant 2004; 4 (Suppl10):72–82